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Background: Rift Valley fever (RVF) is a mosquito-borne viral zoonosis affecting domestic and wild ruminants,
camels and humans. Outbreaks of RVF are characterized by a sudden onset of abortions and high mortality
amongst domestic ruminants. Humans develop disease ranging from a mild flu-like illness to more severe
complications including hemorrhagic syndrome, ocular and neurological lesions and death. During the RVF
outbreak in South Africa in 2010/11, a total of 278 human cases were laboratory confirmed, including 25 deaths.
The role of the host inflammatory response to RVF pathogenesis is not completely understood.
Methods: Virus load in serum from human fatal and non-fatal cases was determined by standard tissue culture
infective dose 50 (TCID50) titration on Vero cells. Patient serum concentration of chemokines and cytokines involved
in inflammatory responses (IL-8, RANTES, CXCL9, MCP-1, IP-10, IL-1β, IL-6, IL-10, TNF and IL-12p70) was determined
using cytometric bead assays and flow cytometry.
Results: Fatal cases had a 1-log10 higher TCID50/ml serum concentration of RVF virus (RVFV) than survivors (p < 0.05).
There were no significant sequence differences between isolates recovered from fatal and non-fatal cases. Chemokines
and pro- and anti-inflammatory cytokines were detected at significantly increased (IL-8, CXCL9, MCP-1, IP-10, IL-10) or
decreased (RANTES) levels when comparing fatal cases to infected survivors and uninfected controls, or when
comparing combined infected patients to uninfected controls.
Conclusions: The results suggest that regulation of the host inflammatory responses plays an important role in the
outcome of RVFV infection in humans. Dysregulation of the inflammatory response contributes to a fatal outcome. The
cytokines and chemokines identified in this study that correlate with fatal outcomes warrant further investigation as
markers for disease severity.
Keywords: Rift Valley fever, Inflammation, PathogenesisBackground
Rift Valley fever (RVF) is a mosquito-borne zoonotic dis-
ease endemic to Africa, the Arabian Peninsula and
islands in the Indian ocean off the east coast of Africa
[1, 2]. RVF virus (RVFV), a member of the Phlebovirus
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infection through the bite of infected mosquitoes or
from contact with infected tissues or body fluids [3, 4].
High mortality rates have been reported in newborn and
juvenile animals, while abortion storms are a prominent
feature of RVF outbreaks in domesticated livestock [1].
Infected humans develop symptoms ranging from mild,
flu-like illness to severe hemorrhagic fever, encephalitis
and death in a small proportion of individuals [5, 6].
The non-structural protein encoded by the small (S)
segment of the virus, NSs, has been implicated as the
major virulence factor. It counteracts antiviral effects ofThis article is distributed under the terms of the Creative Commons Attribution
ons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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assembly of the transcription factor TFIIH, blocking
IFN-α/β transcription through interaction with host
SAP30 protein and post-transcriptional downregulation
of protein kinase R [7–14]. The 14-kDa non-structural
protein encoded by the medium (M) segment, NSm, has
been shown to suppress virus induced apoptosis, and
therefore it is believed that virulence of RVFV is under
polygenic control [15, 16]. There are no commercially
available RVF vaccines or therapeutics for humans, and
the available livestock vaccines require multiple doses or
have adverse effects [17, 18]. However, various vaccine
candidates and experimental therapeutics were recently
developed and tested in animal models [19–28].
The contributory role of human inflammatory re-
sponses to pathogenesis of RVFV infection has not been
intensively studied largely due to lack of clinical mater-
ial. We previously studied the expression of genes in-
volved in innate and adaptive immunity after infection
of BALB/c mice with a lethal dose of RVFV, compared
to similar infection of mice protected by anti-NP im-
munity [29]. Various genes involved in pro-inflammatory
responses and with pro-apoptotic effects were upregu-
lated, and anti-apoptotic genes downregulated in infected
mice with lethal outcome when compared to surviving
mice. However, improperly timed high expression levels of
interleukin-10 (IL-10), an anti-inflammatory immunosup-
pressive cytokine, in mice with a lethal outcome compared
to survivors indicated an imbalance in the regulation of
the inflammatory response, possibly contributing to patho-
genesis and/or immune evasion early after infection [29].
A different study measuring actual protein concentra-
tion in samples from C57BL/6 mice infected with viru-
lent (ZH-501) and attenuated RVFV (MP-12 vaccine
strain) reached the same conclusion, with inflammatory
cytokines significantly elevated in serum, liver and
spleen of ZH-501 infected mice (100 % lethality) com-
pared to those infected with MP-12 (100 % survival). In
addition, a strong pro-inflammatory and anti-apoptotic
response was detected in the brains of ZH-501 com-
pared to MP-12 infected mice, which could explain de-
velopment of neurological disease [30].
Contrary to the abovementioned studies in mice which
showed a correlation between a pro-inflammatory re-
sponse and lethal outcome, a recent study of human
serum collected during the 2000/01 RVF outbreak in Saudi
Arabia from laboratory confirmed cases found the oppos-
ite correlation. A total of 26 human sera, 6 from fatal and
20 from non-fatal cases were tested using a multiplex assay
to determine serum concentration of 39 cytokines [31].
The investigators showed significant differences in concen-
trations of five soluble factors between fatal and non-fatal
cases. Levels of the chemokine GRO (Growth related
oncogene; CXCL1) and soluble CD40L (CD154) weresignificantly elevated in non-fatal vs fatal cases, while the
contrary was true for cytokines IL-1α (proinflammatory)
and IL-10 (immunosuppressive) as well as IL-1RA (a nat-
ural inhibitor that through binding the IL-1R counters the
proinflammatory effects of IL-1α and IL-1β). The investi-
gators concluded from their data that an overall proin-
flammatory response may be associated with patient
survival. The ability of infected individuals to effectively
control replication of RVFV, which is likely affected by
various factors including immune competence, underlying
conditions, co-infections, host genetics and overall health,
contributes to a good prognosis. This is evidenced by data
showing a clear correlation between virus concentration in
serum and disease outcome, with virus replicating on to
an average of 2.3 logs (TCID50) higher in fatal cases com-
pared to non-fatal cases [32].
In this study we evaluated the role of chemokines and
inflammatory cytokines in RVF pathogenicity by testing
stored serum from patients who became infected during
the 2010/11 outbreak of RVF in South Africa. Our results
indicate that individual host innate response to infection,
specifically inflammation, is likely an important contribut-
ing factor to pathogenesis. The up- or downregulation of
certain inflammatory cytokines and chemokines correlated
with either a good prognosis or a lethal outcome of infec-
tion. The data presented in our study further demonstrate
the contributory role of dysregulated inflammatory re-
sponses in host individuals to RVF pathogenesis.
Results
Clinical data
Patients presented with non-specific symptoms such as
fever, myalgia, malaise and headache. More detailed clin-
ical information was available only for a portion of the
fatal cases (n = 18). The information is summarized in
Table 1. Not all of these cases were included in the virus
titer and/or cytokine analysis due to insufficient sample
volume. A total of 12 of the 18 fatal cases had severely
raised liver enzymes (either one or both ALT and AST)
on admission to hospital (liver enzymes could not be mea-
sured in two cases due to poor sample quality or insuffi-
cient volume); 12 had raised urea and creatinine; 16 had
thrombocytopenia; 14 presented with hemorrhagic symp-
toms and four presented with encephalitis. Of note, three
of the four fatal cases that presented with encephalitis
were HIV positive (case submission data). Of the four, two
presented only with encephalitis, one with additional
thrombocytopenia and the last also with hepatitis, renal
failure, thrombocytopenia and hemorrhagic syndrome.
Serum RVF virus titers
Recent infection with RVF virus was confirmed in 278
cases, of which 25 were fatal, by one or more of the fol-
lowing methods: RT-PCR, IgM ELISA, virus isolation.

































SPU100/10 6397 Elevated 13149 Elevated 54 Low n.a. n.a. n.a. n.a. n.a. n.a. Yes
SPU105/10 2965 Elevated 6280 Elevated 50 Low 6.07 Normal 4.9 Normal 96 Normal Yes
SPU59/10 3148 Elevated 6938 Elevated 113 Low 12.6 Elevated 15.5 Elevated 504 Elevated Yes
SPU97/10 1912 Elevated 7824 Elevated 13 Low 1.98 Low 22.3 Elevated 385 Elevated Yes
SPU86/10 8007 Elevated 17719 Elevated 40 Low 6.23 Normal 16.2 Elevated 460 Elevated Yes
SPU162/10 2906 Elevated 6424 Elevated 9 Low 7.91 Normal 34.1 Elevated 711 Elevated Yes
SPU68/10 2991 Elevated 4742 Elevated 2 Low 9.11 Normal 59 Elevated 1421 Elevated Yes
SA1372/10 4710 Elevated 9130 Elevated 13 Low 13.76 Elevated 20.9 Elevated 66.2 Normal Yes
SA1151/10 3079 Elevated 913 Elevated 96 Low 14.28 Elevated 12.6 Elevated 501 Elevated Yes
SA1457/10b 8353 Elevated n.a. n.a. 36 Low 8.96 Normal 16.9 Elevated 188 Elevated Yes
SA979/10 30 Normal 87 Elevated 27 Low 16.85 Elevated 54.3 Elevated 2031 Elevated Yes
SA1598/10a 37 Normal 108 Elevated 49 Low 4.91 Normal 3.3 Normal 55 Low Yes
SA744/10 3359 Elevated 8192 Elevated 8 Low 6.16 Normal 22.6 Elevated 286 Elevated Yes
SA1245/10a 39 Normal 126 Elevated 279 Normal 10.32 Normal 11.5 Elevated 66 Normal No
SA559/10 n.a. n.a. n.a. n.a. 56 Low 2 Low n.a. n.a. n.a. n.a. No
SA663/10 n.a. n.a. n.a. n.a. 65 Low 16.6 Elevated 15.9 Elevated 560 Elevated No
SA596/10 10000 Elevated 14000 Elevated 8 Low 6 Normal n.a. n.a. 647 Elevated No
SA558/10a 46 Elevated 107 Elevated 209 Normal 6.2 Normal 7.1 Elevated 109 Normal No
ALT alanine transferase, AST aspartate transferase. The asterisk (a) indicates the three HIV positive cases, which presented with encephalitis. The hash sign (b) indicates the case which presented with encephalitis but
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13 samples only due to limited volume (n = 8), and a
portion of fatal cases were sampled only after the
viremic stage (n = 4). Of the remaining 253 non-fatal
RVF cases, virus was titrated from 85 samples. The
remaining samples (n = 168) were excluded either due to
insufficient sample volume or because the patients were
no longer viremic at the time of blood collection. Due to
insufficient number of samples taken on individual days
post disease onset, statistical significance of differences
in individual viral loads was calculated on the overall av-
erages spanning all days post onset in fatal and non-fatal
cases. The median serum viral loads, with confidence in-
tervals and p-values to denote statistical significance,
were determined. Individual serum viral loads are shown
in Fig. 1. Blood was collected from fatal cases on average
(median) 5 days post disease onset (range 0 – 10) and
yielded a median viral load of log10 4.5 TCID50/ml
serum (log10 3.7 – 5.3 at 95 % confidence). Blood collec-
tion from non-fatal cases occurred on average (median)
1 day post onset (range 0 – 7) and yielded a median viral
load 1-log lower than that observed for fatal cases (log10
3.5 TCID50/ml serum, range log10 2.9 – 4.1 at 95 % con-
fidence). The differences between fatal and non-fatal
cases of collection post disease onset (p = 0.002) and
viral load (p = 0.04) were statistically significant.Virus whole genome sequences
There were no significant nucleic acid sequence differ-
ences between isolates from fatal (n = 6) and non-fatal

























Fig. 1 Individual and average RVFV viral loads in serum over time. Individu
disease: blue squares indicate individual non-fatal cases and red dots indicate i
by open blue squares (non-fatal) and red circles (fatal). Certain days are represe
shown (days 5, 6, 10). Maximum two samples for respective days were availabSerum cytokine concentrations
From a total of 25 fatal cases, we performed cytometric
bead array (CBA) cytokine analysis only on 19 samples [col-
lected on average (median) 5 days post onset, range 0–10].
The six excluded samples could not be tested due to insuffi-
cient sample volume. A total of 33 serum samples from
non-fatal cases were selected to represent the closest pos-
sible match to days post onset in fatal cases (and based on
available volume) from the outbreak serum panel [collected
on average (median) 2 days post onset, range 0 – 13]. A
total of eight serum samples from healthy and RVF sero-
logically negative (IgM and IgG, results not shown) individ-
uals sampled during a post-outbreak survey were used as
negative controls (representing healthy uninfected persons).
Due to the same limitations as for measuring the viral
loads, statistical significance of differences in cytokine
responses were initially calculated using the overall aver-
ages spanning all days post disease onset. The results
from individual cases are shown along with averages for
specific days, in Table 2 and Fig. 2. For those cytokines
and chemokines showing significant differences when
analyzed using the overall data, the results from fatal
and non-fatal cases were subsequently grouped in two
groups according to early (days 0 – 3) and later periods
(days 4 – 13) after disease onset and analyzed again be-
tween these two groups. The detection of serum tumor
necrosis factor (TNF) and the p70 active heterodimer of
interleukin-12 (IL-12p70) was very low and intermittent
in all sample groups. The overall average concentration
of interleukin-1-beta (IL-1β) was similar in all three
groups, and in general detected at low concentrations.






al viral loads in serum are indicated per each time point post onset of
ndividual fatal cases. Median viral loads at each time point are indicated
nted by only one data point per data set, in which case no medians are
le from fatal cases, thus averages are shown and not medians


























SPU100/10 M 8 Fatal 735.5 18.3 6526.7 592.4 18.3 13.2 317.9 21788.6 49430.5 25448.3 Hemorrhagic
SPU105/10 M 10 Fatal 1486.7 5.4 379.0 96.3 0.0 0.0 665.1 31437.1 33042.3 23176.3 Hemorrhagic
SPU59/10 M 0 Fatal 10046.3 22.0 8956.6 161.0 7.5 0.0 368.6 19185.9 13389.9 27393.0 Hemorrhagic
SPU97/10 M 7 Fatal 15565.7 12.2 54005.5 915.6 2.3 0.0 486.9 1027.3 11008.3 18799.8 Hemorrhagic
SPU86/10 M 5 Fatal 321.8 2.8 321.2 380.8 6.1 0.0 6249.8 7535.9 6135.8 24694.0 No hemorrhagic syndrome
SPU126/10 F 3 Fatal 1312.9 10.1 1371.7 67.9 9.7 0.0 610.4 2612.9 1176.5 28142.4 Sindbis IgM
positive
SPU162/10 F 2 Fatal 585.2 7.0 949.5 83.4 0.0 0.0 285.0 4225.8 758.7 28142.4 Hemorrhagic
SPU115/10 M 0 Fatal 658.7 5.9 476.7 1180.0 0.0 0.0 1325.0 8430.9 1311.4 28335.1
SPU68/10 M 5 Fatal 193.3 5.6 44.0 16.2 34.8 0.0 114.1 1696.1 529.3 25276.2 Hemorrhagic
SA1372/10 M 3 Fatal 1298.1 5.2 300.9 138.4 5.2 5.2 324.7 8670.0 700.1 12711.7 Hemorrhagic, Sindbis
IgM positive
SA1151/10 M 8 Fatal 3320.7 27.7 4873.1 60.6 2.6 5.7 506.2 34137.3 15978.6 21704.5 Hemorrhagic
SA1457/10 M 6 Fatal 385.3 0.0 454.6 110.8 0.0 6.2 2320.6 2790.1 561.5 3829.0 Hemorrhagic; Encephalitis;
HIV status unknown
SA979/10 F 7 Fatal 1524.6 7.3 783.2 5.4 0.0 2.2 457.5 2910.1 747.6 766.1 Normal liver enzymes;
Hemorrhagic; Sindbis
IgM positive
SA1598/10 F 8 Fatal 782.4 4.6 152.7 6.5 0.0 6.2 6043.0 916.4 172.1 323.9 HIV+; encephalitis only; Normal
liver enzymes; No hemorrhagic
syndrome
SA744/10 M 2 Fatal 433.0 0.0 160.3 28.7 2.2 5.0 367.9 4522.6 1430.6 20833.0 Hemorrhagic; Sindbis
IgM positive
SA868/10 M 1 Fatal 543.0 0.0 29.0 133.7 0.0 6.4 7131.7 1429.9 511.8 21451.2
SA486/10 M 3 Fatal 13809.7 21.1 14055.9 126.0 2.4 7.4 1013.1 56734.4 22156.8 19544.4
SA1325/10 M 8 Fatal 6503.5 6.8 940.1 173.2 2.7 6.0 4679.1 28687.8 27127.3 20772.2
SA1448/10 F 5 Fatal 261.8 0.0 39.7 12.0 0.0 5.1 15101.6 392.6 93.6 132.2 Sindbis IgM positive
MEDIAN RESULTS IN FATAL CASES 782.4* 5.9 476.7 110.8*,** 2.3 5.0 610.4***,**** 4522.6*,** 1311.4* 21451.2*,**
SA342/11 M 0 Survivor 303.7 2.6 18.4 0.0 2.3 0.0 24828.0 105.6 1564.9 2754.1 Hospitalized
SA257/10 M 2 Survivor 73.6 0.0 11.9 5.8 0.0 0.0 16970.3 256.3 788.9 5744.4 Hospitalized; Sindbis
IgM positive
SA591/10 M 0 Survivor 69.3 2.7 25.8 0.0 0.0 0.0 4397.4 110.7 4934.3 2100.1 Hospitalized
SA921/10 M 1 Survivor 34.0 8.1 27.6 0.0 0.0 0.0 13747.7 236.0 3330.9 17652.1 Hospitalized











Table 2 Chemokine and cytokine concentrations in individual samples studied (Continued)
SA1329/10 M 0 Survivor 150.2 2.8 47.8 0.0 0.0 0.0 3686.7 300.1 13904.5 10918.3 Hospitalized
SPU079/10 M 0 Survivor 295.7 0.0 32.2 0.0 3.2 3.2 6099.1 196.8 353.9 729.3 Hospitalized; WNV and
Sindbis IgM positive
SA287/10 M 1 Survivor 3764.8 102.7 3403.8 10.8 171.8 2.4 9180.2 486.3 11250.4 15232.2 Hospitalized
SA226/10 M 2 Survivor 1844.0 19.4 864.8 0.0 58.4 2.7 6815.2 330.6 856.5 3805.3 Hospitalized
SA276/10 M 1 Survivor 1341.5 8.1 370.1 6.7 5.0 0.0 4776.0 329.6 8724.8 7047.2 Hospitalized
SA918/10 M 2 Survivor 4657.3 36.9 8.0 0.0 0.0 0.0 12142.9 203.1 1695.4 614.6 Hospitalized
SA399/10 M 0 Survivor 265.7 0.0 51.4 32.5 0.0 2.8 7936.6 307.3 5832.6 17407.5 Hospitalized
SPU062/10 M 3 Survivor 132.7 3.0 127.8 6.7 0.0 0.0 17843.0 247.2 3465.7 10816.4
SA165/10 F 3 Survivor 115.9 0.0 10.5 0.0 0.0 0.0 6680.6 104.0 325.9 2923.9 Sindbis IgM positive
SA197/10 M 13 Survivor 296.0 7.6 309.8 70.2 0.0 0.0 4570.4 7520.5 9217.3 17978.2
SA472/10 M 7 Survivor 499.6 9.4 314.3 0.0 0.0 0.0 8316.3 224.0 3069.1 5206.3 SIndbis IgM positive
SA538/10 M 5 Survivor 54.2 4.9 79.3 0.0 0.0 0.0 10259.9 119.9 2392.9 3561.4
SA746/10 M 4 Survivor 10789.3 202.8 3228.9 0.0 0.0 0.0 16001.6 138.9 4062.4 1010.0
SA982/10 F 0 Survivor 469.1 14.9 179.8 13.6 0.0 0.0 16421.8 368.5 3479.0 8817.0
SA1098/10 M 1 Survivor 41.6 9.0 9.6 0.0 0.0 0.0 18602.3 158.4 238.0 3599.2
SA327/11 F 2 Survivor 1893.6 8.8 17.2 0.0 0.0 0.0 12504.9 254.7 729.4 2622.1
SA250/10 M 1 Survivor 77.4 0.0 25.7 0.0 0.0 0.0 6213.1 79.0 490.3 918.4
SA317/10 M 2 Survivor 148.8 5.8 48.1 0.0 0.0 0.0 5102.8 92.0 449.0 2365.6
SA093/10 M 2 Survivor 166.3 2.7 26.6 0.0 2.2 0.0 8480.4 372.3 2214.5 10447.3
SA128/10 M 1 Survivor 20.3 0.0 40.3 0.0 0.0 0.0 19184.5 226.6 2179.7 8363.5
SA296/10 M 0 Survivor 121.2 5.1 94.2 0.0 0.0 5.5 5810.2 216.9 1849.5 1286.1
SA325/10 M 2 Survivor 256.8 0.0 9.1 0.0 0.0 4.9 7534.2 135.3 772.8 2357.4
SA1402/10 M 0 Survivor 136.1 0.0 53.4 0.0 0.0 3.2 5295.1 289.9 4027.0 8440.0
SPU085/10 M 0 Survivor 175.5 0.0 26.8 0.0 0.0 2.7 8815.6 104.6 1520.0 2786.1
SPU129/10 M 3 Survivor 171.2 5.5 22.4 0.0 0.0 0.0 19191.9 461.4 626.6 4289.8
SA139/10 M 2 Survivor 97.9 0.0 17.4 0.0 0.0 5.3 14600.1 217.2 1064.3 4000.9 WN and Sindbis
IgM positive
SA494/11 M 3 Survivor 51.5 0.0 7.4 0.0 0.0 2.6 19758.2 85.0 553.5 832.6
SA523/11 M 5 Survivor 36647.8 921.1 3744.2 0.0 2.7 3.3 19391.7 101.1 539.4 900.0
MEDIAN RESULTS IN SURVIVORS 171.2* 4.9 40.3 0.0 0.0 0.0 8815.6 217.2 1695.4* 3599.2*
SPU332/10/28 M N/A Control 14.5 6.0 5.7 0.0 0.0 0.0 4606.7 63.2 213.7 9.3











Table 2 Chemokine and cytokine concentrations in individual samples studied (Continued)
SPU332/10/27 M N/A Control 46.8 6.2 13.1 0.0 0.0 0.0 17658.3 2179.3 501.1 368.2
SPU332/10/11 F N/A Control 218.1 8.9 5.8 0.0 0.0 0.0 15274.5 31.2 37.4 0.0
SPU332/10/2 M N/A Control 202.8 0.0 21.2 0.0 0.0 2.2 14419.2 843.8 601.2 196.2
SPU332/10/6 M N/A Control 28.5 0.0 0.0 0.0 0.0 2.2 24540.3 132.2 45.9 24.0
SPU332/10/8 F N/A Control 37.2 5.0 7.5 0.0 0.0 4.8 17996.2 227.5 20.5 19.3
SPU332/10/25 M N/A Control 9.5 0.0 0.0 0.0 0.0 2.4 54.8 0.0 0.0 0.0
MEDIAN RESULTS IN CONTROLS 37.5 2.5 6.4 0.0 0.0 1.1 15433.8 179.8 129.8 21.6
* denotes statistical significant increase relative to results in controls (p < 0.01)
** denotes statistical significant increase relative to results in survivors (p < 0.01)
*** denotes statistical significant decrease relative to results in controls (p < 0.01)
**** denotes statistical significant decrease relative to results in survivors (p < 0.01)



































































































































































































































Days post disease onset
IL-12p70
Fig. 2 (See legend on next page.)
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Fig. 2 Individual and average cytokine concentrations in serum over time. Individual cytokine concentrations in serum are indicated per each time point
post onset of disease: blue squares indicate individual non-fatal cases and red dots indicate individual fatal cases. Average concentrations at each time
points are indicated by open blue squares (non-fatal) and red circles (fatal). The continuous green line indicates the average concentration in negative
control samples (RVF naïve individuals) and thus has no bearing on the days indicated on the x-axis. Certain days are represented by only one data point
per data set, in which case no medians are shown (days 1, 4, 6, 10 and 13). For days where less than three samples were available per dataset, averages
are shown instead of medians. Note: because of the 1:4 dilution of serum for the cytokine analysis, a “0 pg/ml” value represents a limit of detection rather
than absolute absence of the detected protein
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(CXCL10/IP-10) and interleukin-10 (IL-10) were signifi-
cantly increased in samples from fatal cases relative to
survivors and controls using the overall data. When
comparing early samples (day 0 – 3; p = 0.08) and later
samples (day 4 – 13; p = 0.03) from fatal cases to non-
fatal cases, the differences in CXCL9/MIG concentration
were not statistically significant. CXCL10/IP-10 was sig-
nificantly increased in early samples (p < 0.0001) from
fatal cases compared to early samples from non-fatal
cases, but not in later samples (p = 0.06). When compar-
ing IL-10 levels in early (p = 0.12) and later (p = 0.05)
samples from fatal and non-fatal cases as opposed to
using overall data, differences were not statistically sig-
nificant. Serum levels of Interleukin-8 (IL-8/CXCL8) and
monocyte chemotactic protein-1 (CCL2/MCP-1) were
significantly increased in samples from fatal cases and
non-fatal cases compared to negative controls, but not
between fatal and non-fatal cases when using overall
data. Interestingly, three fatal cases (SA979/10, SA1598/
10 and SA1448/10) had significantly lower IP-10 levels
compared to other fatal cases. Interleukin-6 (IL-6) serum
levels were substantially higher (>10 fold) in serum from
fatal cases compared to non-fatal cases and negative con-
trols, but the differences were not statistically significant
(p = 0.13 and 0.1) due to substantial variations in samples
from fatal cases. IP10 and IL-6 were also increased in sur-
vivors relative to controls, but to lower levels than in fatal
cases and not with statistical significance in the case
of IL-6. It is noteworthy that chemokine ligand 5
(CCL5/RANTES) was significantly decreased in serum
from fatal cases compared to survivors and controls using
overall data. Serum samples collected from fatal cases
early after onset contained significantly less RANTES than
serum from non-fatal cases collected in the same time
frame (p < 0.0001). The decreased RANTES in later sam-
ples from fatal cases compared to non-fatal cases was also
statistically significant (p = 0.01).
Three of the fatal patients had strikingly low concentra-
tions of IP-10 compared to the median of 21451.19 pg/ml
in fatal cases. Clinical data were unavailable for one of these
cases but interestingly the remaining two did not present
with any liver involvement (normal liver enzyme counts). A
heat-map diagram showing relative levels of each chemo-
kine or cytokine is shown in Fig. 3, with main functions inthe host response to infection. Positive correlations were
observed when comparing viral load in fatal cases to IP-10
(r = 0.649; p = 0.003) and TNF (r = 0.521; p = 0.022) re-
spectively (Fig. 4). Positive correlations were observed when
comparing viral load to IP-10 (r = 0.548; p = 0.01) and MIG
(r = 0.575; p = 0.008) in a subset of the non-fatal cases
(non-hospitalized patients; n = 21). No other statistically
significant correlations were observed.
Discussion
The clinical manifestations of severe RVF during the
2010/11 RVF outbreak in South Africa included liver
failure, renal failure, thrombocytopenia, encephalitis and
hemorrhaging; they are similar to those reported previ-
ously [5]. A small number of both fatal and surviving pa-
tients had IgM antibodies against other common
arboviral diseases in South Africa, including West Nile
virus and Sindbis virus. The high percentage of positive
HIV status amongst RVF cases associated with encephal-
itis noted in our study corresponds to earlier observa-
tions. A high percentage (89 %) of human cases during
the 2007 Tanzania outbreak presented with encephalop-
athy and all patients with known HIV status, of whom
75 % died, were among this group [6].
It was previously shown that RVFV replicates to sig-
nificantly higher levels in patients with fatal outcome
compared to survivors [32]. Our results point to the
same conclusion, but we only found a 1-log10 difference
in average virus titer (TCID50/ml) in serum between
fatal and non-fatal cases, compared to a 2.3 log10 differ-
ence shown in the previous study. This difference is
likely due to differences in time of sample collection
post disease onset. Samples were collected on average
3 days post onset from both fatal and non-fatal cases in
the previous study (ranges 1–7 days from fatal, and 0 to
10 days from non-fatal), compared to 5 days from fatal
(range 0–10) and 1 day post onset (range 0–7) from
non-fatal cases in this study. The immune response of
the host plays a role in the pathogenesis and thus the se-
verity of disease in an infected individual. Dates of dis-
ease onset were recorded by healthcare professionals at
the hospitals, clinics or general practitioners consulted
by patients. Day post onset of blood collection from a
number of cases was established as zero (0) due to onset
date being recorded as the same date as blood collection.
Fig. 3 Heatmap showing relative chemokine and cytokine levels between fatal cases, non-fatal cases and negative controls. Relative levels are indicated
by color. Red indicates a high level, orange indicates an intermediate level, blue indicates a low level and absence of color indicates that no protein was
detected. Brackets indicate differences which are statistically significant (p < 0.01)
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RVF during the outbreak resulting in sick people seeking
medical attention immediately upon feeling unwell. One
can, however, not rule out incorrect information re-
corded by professionals or incorrect/inaccurate informa-
tion supplied by patients, which is a limitation of this
study. There was no significant sequence difference be-
tween isolates recovered from fatal and non-fatal cases.
The role of the host inflammatory response in RVF
disease development has not been extensively studied
and most studies have been conducted in laboratory ani-
mal models which do not necessarily accurately reflect
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more knowledge of this aspect of RVF pathogenesis.
Although, on average, samples were collected later
after onset of illness from fatal cases than survivors, the
inclusion of data from healthy control individuals serves
to normalize the data within the period of acute RVFV
infection. To further account for the possible effect of
sample time collection, data were compared between
fatal and non-fatal cases using the overall dataset, and
further grouped according to early and later time points
after disease onset. The very low to absent detection of
IL-1β and TNF corresponds to the previous study using
human samples [31]. Similar to the previous study, we
found an increase in the immunosuppressive cytokine
IL-10 in fatal cases, while the previous study also found
an increase in pro-inflammatory cytokines CXCL1/GRO,
which binds to one of the IL-8 receptors CXCR2, and
sCD40L in survivors leading the authors to conclude
that a pro-inflammatory response is indicative of survival
from RVFV infection [31]. In contrast, we found that
upregulation of certain proinflammatory cytokines sig-
nificantly correlates with a fatal outcome, which corre-
sponds to the two previous studies in mice and is likely
influenced by the specific cytokines analyzed in the dif-
ferent studies [29, 30].
In this study IL-6 and IL-8, were detected at similar
levels in fatal cases and survivors, and were increased
when grouped together as RVFV infected individuals
(fatal cases and survivors) compared to uninfected indi-
viduals (negative controls). Both cytokines can play a
role in inflammation, which confirms that, regardless of
disease outcome, inflammation is triggered during RVFV
infection in humans, as has been reported in other viral
hemorrhagic fevers [33–37]. Interleukin-8 (IL-8) is a
pro-inflammatory mediating chemokine produced by
macrophages in response to infection, while IL-6 is an
inflammatory cytokine that also mediates fever. It’s im-
portant to note that fatal outcome from Ebola virus dis-
ease (EVD) correlates strongly with significantly higher
IL-6 and IL-8 compared to non-fatal outcome [38], con-
trary to our results which show similar levels of both in
fatal cases and survivors. However,, EVD has a notably
higher fatality rate than RVF and their etiologic agents
have different mechanisms by which they counteract
host immune responses. A higher level of both cytokines
are indicative of liver involvement and damage, as IL-8
has been shown to strongly contribute to liver inflamma-
tion [39] while IL-6 is involved in liver regeneration after
damage [40].
The following pro-inflammatory chemokines were signifi-
cantly increased in fatal cases when compared to survivors
and negative controls: CXCL9/MIG and CXCL10/IP-10; or
in fatal cases and survivors compared to negative controls:
CCL2/MCP-1. The chemokines CXCL9 and CXCL10 bindto the same receptor CXCR3. These results correspond to
observations on other viral hemorrhagic fevers (VHFs) such
as hemorrhagic fever with renal syndrome (HFRS), Severe
Fever with Thrombocytopenia (SFTS), Crimean-Congo
hemorrhagic fever (CCHF) and Ebola virus disease (EVD)
[33–38, 41]. The proinflammatory chemokines are involved
in the mobilization of various immune cells to the site of in-
fection that include natural killer cells, dendritic cells, and
monocytes/macrophages. It is also interesting that three fatal
cases that had very low levels of IP-10 compared to other
fatal cases (between 27 and 60 fold lower compared to me-
dian for the fatal group), which corresponded to absence of
liver failure in two (detailed clinical information not available
for the third). The positive correlation between viral load
and IP-10 found in fatal cases and non-fatal cases (non-hos-
pitalized) suggests that high viral load possibly contributed
to liver damage in the individuals in this study.
It is noteworthy that the immunosuppressive anti-
inflammatory IL-10 was also increased in fatal cases versus
survivors and negative controls, which suggests an imbal-
ance in inflammatory response, however increased IL-10 is
a common occurrence in patients infected with VHF path-
ogens mentioned above. Interestingly the serum concentra-
tion of CCL5/RANTES, a chemokine also involved in
chemotaxis of lymphocytes, monocytes, and eosinophils,
was significantly decreased in fatal cases compared to sur-
vivors and negative controls. RANTES plays a role in the
activation and proliferation of T-cells and is thus pro-
inflammatory, further pointing towards the dysregulation of
the inflammatory response during RVF infection. RANTES
levels have been shown to be low in severe and fatal cases
of bacterial sepsis, meningococcal disease, Chikungunya
fever and cerebral malaria in children [42–45]. Two studies
have shown similar levels of RANTES during infection with
Ebola and Sudan viruses, when comparing fatal to non-fatal
cases [37, 38], while a recent study found increased
RANTES levels in surviving pediatric Ebola virus disease
patients [46]. RANTES is released by a variety of cell types,
including platelets [47–50] which play a major role in blood
clotting. From the limited number of fatal cases for which
more detailed clinical information was available (n = 18),
four did not display hemorrhagic manifestations. Two of
these were not included in our cytokine analysis due
to insufficient sample volume. However, we noted
that the remaining two non-hemorrhagic cases,
which were included in the cytokine analysis, had
strikingly higher levels of RANTES (10 fold at
6249.81 pg/ml and 6042.98 pg/ml) compared to
other fatal cases (median 610.4 pg/ml). Although
statistically weak in terms of sample numbers, this
result is interesting and might point towards an as-
sociation of low RANTES and hemorrhagic manifest-
ation of RVF. No correlation was observed between
platelet counts and RANTES levels (R2 = 0.005)
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not available for non-fatal cases.
When the fatal and non-fatal datasets were grouped
according to early and later after disease onset, only two
cytokine/chemokine concentration differences remained
statistically significant; RANTES (early and later after
disease onset) and IP-10 (early after onset). The loss of
statistical significance of factors previously identified as
significant in the overall groups is likely due to the de-
creased sample numbers once data were stratified ac-
cording to time. A very strict alpha (α) value of 0.01 was
also used as opposed to the usual 0.05 to ensure robust-
ness of statistical conclusions.
A number of the cytokines and chemokines that were
raised or decreased in fatal cases versus survivors and nega-
tive controls, were in turn also significantly, albeit to a
much lesser extent, raised or decreased when comparing
RVF survivors to negative controls. This indicates that a
certain level of inflammation is normally elicited by RVFV
infection, even when the host is able to overcome the infec-
tion, but that the inflammatory response in these surviving
individuals is much less severe and at a more appropriate
level, or that the ability to terminate inflammatory re-
sponses were less effective in fatal cases. Inflammatory cy-
tokines and chemokines form an integral part of the innate
response to infection, responsible for recruiting and activat-
ing various immune cells and acting as co-stimulatory sig-
nals to induce adaptive immunity. Therefore a certain level
of elevated cytokines is required for a host to mount an ef-
ficient immune response to infection. The balance and level
of these cytokines seem to be very important in RVF, with
dysregulation likely contributing to a fatal outcome. The
underlying host factors that might contribute to either a
well-controlled or uncontrolled inflammatory response
during RVFV infection and other hemorrhagic fever virus
infections remains to be investigated. These differential re-
sponses and outcomes, aside from the extent of viral ex-
posure, are likely influenced by host genetics, lifestyle, diet,
underlying conditions or medication.
Conclusions
An uncontrolled inflammatory response to RVFV infec-
tion correlated with a fatal outcome in certain individ-
uals infected with the virus during the 2010/11 RVF
outbreak in South Africa. The cytokines identified in our
study could be used as indicators of fatal outcome, but
more importantly could help focus efforts on treatment
therapies, possibly those aimed at decreasing the effects
of an aberrant inflammatory response.
Methods
Patient samples
During the 2010/11 RVF outbreak in South Africa, human
serum samples from suspected RVF cases were submittedto the Centre for Emerging and Zoonotic Diseases, Na-
tional Institute for Communicable Diseases (NICD-NHLS),
for laboratory confirmation, which included screening for
other arboviral infections [51]. Of a total of 278 laboratory
confirmed cases, 104 sera were analyzed in the study, of
which 19 were from fatal, and 85 from non-fatal cases. Sera
were separated from clotted blood and aliquoted for rou-
tine diagnostic testing and −70 °C storage for follow-up
testing. Ethical clearance for the use of the samples was ob-
tained from the University of the Witwatersrand Hu-
man Research Ethics Committee (HREC), clearance
number M120239.
Virus titration
Titration of virus in human serum was performed as de-
scribed previously [52] by preparing quadruplicate tenfold
dilutions in culture medium on microtiter (96-well) tissue
culture plates, addition of Vero cells and incubation at
37 °C in 5 % CO2 incubator for up to 14 days. Cytopathic
effects (CPE) were recorded and virus titers calculated by
the Kärber method [53] were expressed as median tissue
culture infectious dose (TCID50) per ml of serum. Only
serum samples of sufficient volume, and from which virus
was isolated in suckling mice and/or viral RNA detected
by RT-PCR during the diagnostic process, were subjected
to TCID50 titration (n = 98 serum samples).
Whole genome sequencing of RVFV isolates
A total of 12 viral isolates (first passage on Vero cells)
were selected for whole genome sequencing, consisting
of six isolates from fatal cases and six isolates from non-
fatal cases. Vero cells were infected with human serum
and grown until 80–90 % CPE. To avoid accumulation
of misleading mutations in the virus genome during
in vitro passaging of virus in Vero cells, we sequenced
first passage Vero isolates. Supernatants (SNF) were har-
vested, clarified of cellular debris and RNA extracted
from 140 μl SNF using the QIAamp viral RNA kit
(Qiagen, Germany). RVF genome specific primers de-
scribed previously [54] were used to amplify whole S
and M segments and two overlapping fragments of the L
segment using a Titan One step RT-PCR kit (Roche,
Germany). RT-PCR products were cleaned up using a
Promega Wizard PCR clean up system (Promega, USA).
Sequencing was outsourced to the Stellenbosch Univer-
sity Central Analytical Facilities (SUN-CAF) and per-
formed as follows. Purified amplicons were barcoded
and sequenced using 316 Chips with 200 bp chemistry
on an Ion PGM™ system (Life Technologies, USA). Ana-
lysis of sequence data were performed using the Torrent
Suite software. Reads were mapped to Genbank consensus
sequence (NCBI BioProject PRJNA14631) using Mira
version 3.9.18 (http://mira-assembler.sourceforge.net/) to
obtain a FASTA file.
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(CBA)
A total of 60 serum samples were selected for CBA ana-
lysis. This total consisted of 19 serum samples from fatal
cases, 33 serum samples from non-fatal cases and eight
serum samples from uninfected persons (healthy con-
trols) sampled in a post-outbreak survey. The samples
from infected patients (fatal and non-fatal) consisted of
a selection of sera virologically or serologically labora-
tory confirmed cases. Available sample volume was a
limiting factor with regards to the selection of samples
for this particular analysis.
All serum samples were tested in duplicate at 1:4 di-
lution and CBA kits designed to measure specific sets
of cytokines were used. The BD CBA Human Chemokine
kit (Becton, Dickinson and Company, USA) was used to
quantitatively measure interleukin-8 (IL-8), RANTES
(CCL5), monokine induced by interferon-gamma (CXCL9/
MIG), monocyte chemoattractant protein-1 (MCP-1) and
interferon-gamma-induced protein-10 (IP-10). The BD CBA
Human Inflammatory Cytokines kit (Becton, Dickinson and
Company, USA) was used to quantitatively measure IL-8,
interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-10
(IL-10), tumor necrosis factor (TNF) and interleukin-12p70
(IL-12p70). Assays were performed according to the manu-
facturer’s instructions. Flow cytometry was performed using
a dual-laser BD FACSCalibur™ system (BD Biosciences,
USA) utilizing BD CellQuest™ software for acquisition.
Dilution series of human cytokine standards, included in
each kit and prepared according to the manufacturer’s in-
structions, were included in each assay run to enable quanti-
fication. Data were analyzed using FCAP Array software
v1.0. Note IL-8 was analyzed with both kits and although
concentrations of the cytokine differed slightly due to the
difference in preparation steps between the kits, the out-
come of fatal versus non-fatal and healthy controls were the
same, thus only results from the Chemokine kit is shown.
The relationship between serum levels of cytokines
and viral load (log) was evaluated using the Spearman
correlation coefficient. Obvious outliers were excluded
from analyses.Statistics
Equality of variance of cytokines/chemokines between
fatal and non-fatal cases was calculated for each cytokine/
chemokine analyzed using the F-test in Microsoft Excel
Analysis ToolPak. Confidence intervals and p-values (two
sample T-test assuming either equal or unequal variance
depending on the outcome of the F-test) were calculated
using Microsoft Excel Analysis ToolPak. The alpha (α)
value was set to 0.01 to ensure high confidence in statis-
tical significance. Comparison of viral load and cytokine
levels was performed using the Spearman correlationcoefficient. SPSS software (SPCC Inc., Chicago, Illinois)
were used for these statistical analyses.
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